Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

NORDIC BIOTECH ADVISORS ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.8% 0.8%   Bankruptcy risk   4.3% 2.9% 5.3% 2.0% 1.7% 2.1% 9.0% 9.0%   Credit score (0-100)   49 60 42 67 72 66 27 27   Credit rating   BBB BBB BBB A A A BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.4 5.6 0.5 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   3,369 3,300 2,730 3,700 3,812 4,496 0.0 0.0   EBITDA   -37.1 251 -233 1,005 1,292 1,815 0.0 0.0   EBIT   -179 121 -341 967 1,270 1,809 0.0 0.0   Pre-tax profit (PTP)   -202.9 102.2 -387.1 936.6 1,239.9 1,832.0 0.0 0.0   Net earnings   -119.4 80.8 -301.4 657.3 942.7 1,432.6 0.0 0.0   Pre-tax profit without non-rec. items   -203 102 -387 937 1,240 1,832 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   213 135 56.7 29.3 6.4 0.0 0.0 0.0   Shareholders equity total   2,022 2,103 1,802 2,459 3,402 4,834 4,709 4,709   Interest-bearing liabilities   26.1 119 11.3 11.3 11.3 11.3 0.0 0.0   Balance sheet total (assets)   2,522 2,960 2,531 3,241 4,261 5,255 4,709 4,709   Net Debt   -801 -1,249 -1,233 -2,028 -2,797 -3,011 -4,709 -4,709     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   3,369 3,300 2,730 3,700 3,812 4,496 0.0 0.0   Gross profit growth   7.0% -2.1% -17.3% 35.5% 3.0% 17.9% -100.0% 0.0%   Employees   2 0 2 2 2 2 0 0   Employee growth %   33.3% -100.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   2,522 2,960 2,531 3,241 4,261 5,255 4,709 4,709   Balance sheet change%   -8.3% 17.4% -14.5% 28.1% 31.5% 23.3% -10.4% 0.0%   Added value   -37.1 251.1 -232.6 1,004.8 1,307.5 1,815.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -223 -208 -187 -65 -46 -13 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 1.0 -1.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -5.3% 3.7% -12.5% 26.1% 33.3% 40.2% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -6.8% 4.6% -11.1% 34.3% 33.9% 38.9% 0.0% 0.0%   ROI %   -8.5% 5.9% -17.8% 45.0% 43.1% 44.8% 0.0% 0.0%   ROE %   -5.7% 3.9% -15.4% 30.9% 32.2% 34.8% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   80.2% 71.0% 71.2% 75.9% 79.8% 92.0% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   2,157.4% -497.2% 530.4% -201.8% -216.4% -165.9% 0.0% 0.0%   Gearing %   1.3% 5.7% 0.6% 0.5% 0.3% 0.2% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   109.1% 33.6% 44.3% 235.2% 243.6% 174.3% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   3.6 2.7 2.7 3.5 4.3 12.2 0.0 0.0   Current Ratio   3.6 2.7 2.7 3.5 4.3 12.2 0.0 0.0   Cash and cash equivalent   827.1 1,367.9 1,244.7 2,039.0 2,808.6 3,022.2 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,301.4 1,448.9 1,235.9 1,921.8 2,857.1 4,691.2 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -19 0 -116 502 654 908 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -19 0 -116 502 646 908 0 0   EBIT / employee   -90 0 -171 483 635 904 0 0   Net earnings / employee   -60 0 -151 329 471 716 0 0